On February 26, 2025 Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, reported receipt of a Notice of Allowance from the Chinese Patent Office, for City of Hope’s patent application number 201880064280.9 which protects the CD19-expressing oncolytic virus, onCARlytics (Press release, Imugene, FEB 26, 2025, View Source [SID1234650549]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The patent, titled "ONCOLYTIC VIRUS EXPRESSING A CAR T CELL TARGET AND USES THEREOF" protects the method of composition and method of use of onCARlytics through to 2038.

Exclusively licensed to Imugene, OnCARlytics is a CD19-expressing oncolytic virus that enters solid tumour cells and forces them to express the CD19 protein on the cell surface, presenting a target for CD19 targeting therapies.

Imugene’s OASIS dose escalation trial of onCARlytics is being conducted at up to ten sites in the United States, with up to approximately 40 patients proposed to take part in the trial.

Imugene MD & CEO Leslie Chong said: "Intellectual property has remained a priority for our innovative range of immuno-oncology assets, and to have onCARlytics protected in a major market like China is an integral part of this strategy."

On February 26, 2025 Neogap Therapeutics AB, a Swedish clinical-stage biotechnology company, reported that it has been awarded a USD 125,000 ScaleReady G-Rex Grant to optimise the development and manufacturing of its innovative personalised cancer immunotherapy, pTTL (Press release, Neogap Therapeutics, FEB 26, 2025, View Source;g-rex-grant-to-advance-personalised-cancer-immunotherapy,c4110383 [SID1234650547]). The funding supports Neogap’s efforts to further advance the manufacturing of their cell therapy product by developing a bioreactor process able to support large-scale manufacturing.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The G-Rex Grant is part of ScaleReady’s USD 20 million programme aimed at advancing Cell and Gene Therapy (CGT) development and manufacturing. With this funding, Neogap Therapeutics will optimise manufacturing for pTTL (personalised Tumour Trained Lymphocytes), an ATMP (Advanced Therapy Medicinal Product) that combines EpiTCer technology with the PIOR AI platform.

Designed to target neoantigens with precision, pTTL uses the patient’s immune cells to generate tumour-specific T cells. It is currently being evaluated in a Phase I/IIa clinical trial in patients with advanced colorectal cancer.

"We are very excited to have been selected for this significant grant from ScaleReady and look forward to incorporating the G-Rex platform into our pTTL manufacturing process," says Kristine Bylund, Head of Cell Therapy Production and Development at Neogap Therapeutics. "Our development team has already completed preliminary experiments, and this grant will allow us to continue the development of a robust and cost-effective bioreactor process required to meet our quality and safety standards for clinical production, bringing us closer to our goal of delivering personalised medicine to patients in need."

"We are fortunate to have the opportunity to help Neogap develop a cost-effective G-Rex centric manufacturing process to create personalised Tumour Trained Lymphocytes. Neogap’s novel approach has the potential to make a highly favorable impact on clinical outcomes for patients with advanced colorectal cancer and are grateful for the opportunity to participate," says John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex. ​

About Neogap’s immunotherapy, pTTL
pTTL (personalised Tumour Trained Lymphocytes) is a cell-based immunotherapy that enhances the patient’s own T cells to fight cancer. The therapy combines advanced DNA analysis with T-cell expansion in a precision treatment for solid tumours. It is based on Neogap’s patented technologies, PIOR and EpiTCer. The goal is to provide patients with a tailored and innovative therapy that meets their specific needs.

On February 25, 2025 Santo Therapeutics reported recruitment of subjects for NF2 gene mutation-related solid tumors is now officially open.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

An open-label, single-arm, dose-escalation clinical study initiated by the Cancer Hospital of the Chinese Academy of Medical Sciences to evaluate the safety, tolerability, and preliminary efficacy of ST002 in patients with NF2 gene mutation-related solid tumors is now officially recruiting patients. The study drug is ST002 injection. Patients participating in this study will receive free access to the relevant examinations specified in the protocol, as well as the study drug .

The subjects recruited for this study should meet the following criteria:

1) Age ≥ 16 years old, gender not limited;

2) Benign or malignant solid tumors that meet the diagnostic criteria for NF2 gene mutation and have no standard treatment or have failed standard treatment;

3) There is at least one measurable and injectable superficial lesion, with the longest diameter of the tumor lesion baseline at the injection site >1.0 cm ;

4) It has sufficient organ and bone marrow function;

5) Patients must voluntarily participate in clinical trials, have good compliance, cooperate well with researchers, and sign a written informed consent form .

If you meet these key inclusion criteria and are willing to participate in this study, please contact us. After screening, a doctor will ultimately determine your eligibility and ability to participate in the study.

Recruitment period: From now on

Contact Person 1:Teacher Jiang 13261010586

Contact Person 2: Teacher Ma17349862185

(Press release, Santo Therapeutics, FEB 25, 2025, View Source;scene=1&srcid=03241eumHGHbS9qU0zullwfF&sharer_shareinfo=ee7432f17f07e091e676530751b67beb&sharer_shareinfo_first=ee7432f17f07e091e676530751b67beb#rd [SID1234663814])

On February 25, SinocellTech reported that its independently developed recombinant humanized anti- PD-1 IgG4 monoclonal antibody, fenolimab (Anyouping , SCT – I10A ), combined with the recombinant humanized anti -VEGF monoclonal antibody bevacizumab, received official approval from the China National Medical Products Administration ( NMPA ) for the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma ( HCC ) who have not received prior systemic therapy (Press release, Sinocelltech, FEB 25, 2025, View Source [SID1234656253]). Following its approval as a first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma, SinocellTech secured its second indication in the PD-1 arena .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On February 25, 2025 Orion reported annual report for the year 2024 (Presentation, Orion, FEB 25, 2025, View Source [SID1234654276]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!